A Randomised, Placebo Controlled, Double-Blind, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1103 in Healthy Adult Male Subjects.

Trial Profile

A Randomised, Placebo Controlled, Double-Blind, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1103 in Healthy Adult Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Atesidorsen (Primary)
  • Indications Cancer; Diabetic retinopathy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 07 Dec 2011 Primary endpoint 'Pharmacokinetic-parameters' has been met.
    • 07 Dec 2011 Status changed from active, no longer recruiting to completed, according to an Antisense Therapeutics media release.
    • 07 Dec 2011 Primary endpoint 'Drug-concentration' has been met, according to an Antisense Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top